{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:08:14Z","timestamp":1773644894661,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,5,22]],"date-time":"2002-05-22T00:00:00Z","timestamp":1022025600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Fam Pract"],"DOI":"10.1186\/1471-2296-3-10","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:42:27Z","timestamp":1034361747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]"],"prefix":"10.1186","volume":"3","author":[{"given":"Eduardo","family":"Collantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Wing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin","family":"Melian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng L","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana B","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogera L","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R","family":"Lines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry J","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Etoricoxib Rheumatoid Arthritis Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,5,22]]},"reference":[{"key":"18_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.1780390503","volume":"39","author":"American College of Rheumatology Ad Hoc Committee on clinical guidelines","year":"1996","unstructured":"American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 723-731.","journal-title":"Arthritis Rheum"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.1780390502","volume":"39","author":"American College of Rheumatology Ad Hoc Committee on clinical guidelines","year":"1996","unstructured":"American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996, 39: 713-722.","journal-title":"Arthritis Rheum"},{"key":"18_CR3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"MM Wolfe","year":"1999","unstructured":"Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999, 340: 1888-1899. 10.1056\/NEJM199906173402407.","journal-title":"N Engl J Med"},{"key":"18_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0002-9343(91)90118-H","volume":"91","author":"JF Fries","year":"1991","unstructured":"Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991, 91: 213-222.","journal-title":"Am J Med"},{"key":"18_CR5","first-page":"14.1","volume-title":"In: Rheumatology","author":"PLCM van Riel","year":"1998","unstructured":"van Riel PLCM, Wijnands MJH, van de Putte LBA: Evaluation and management of active inflammatory disease. In: Rheumatology. Edited by: Klippel JH, Dieppe PA, Arnett FC. 1998, London: Mosby, 14.1-14.2. 2nd","edition":"2nd"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000, 343: 1520-1528. 10.1056\/NEJM200011233432103.","journal-title":"New Engl J Med"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","volume":"21","author":"TJ Schnitzer","year":"1999","unstructured":"Schnitzer TJ, Truitt K, Fleischmann R, et al: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics. 1999, 21: 1688-1702. 10.1016\/S0149-2918(99)80048-4.","journal-title":"Clinical Therapeutics"},{"key":"18_CR8","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"P Emery","year":"1999","unstructured":"Emery P, Zeidler H, Kvien KT, et al: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet. 1999, 354: 2106-2111. 10.1016\/S0140-6736(99)02332-6.","journal-title":"Lancet"},{"key":"18_CR9","volume-title":"J Rheumatology","author":"A Matsumoto","year":"2002","unstructured":"Matsumoto A, Melian A, Mandel DR, et al: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatology. 2002,"},{"key":"18_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-735.","journal-title":"Arthritis Rheum"},{"key":"18_CR11","first-page":"S299 [Abstract]","volume":"43","author":"K Malmstrom","year":"2000","unstructured":"Malmstrom K, Shahane A, Fricke JR, Ehrich E: MK \u20130663\u2013an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model. Arthritis Rheum. 2000, 43: S299 [Abstract]-","journal-title":"Arthritis Rheum"},{"key":"18_CR12","first-page":"S144 [Abstract]","volume":"42","author":"K Gottesdiener","year":"1999","unstructured":"Gottesdiener K, Schnitzer T, Fisher C, et al: MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee. Arthritis Rheum. 1999, 42: S144 [Abstract]-","journal-title":"Arthritis Rheum"},{"key":"18_CR13","first-page":"133 [Abstract]","volume":"59","author":"K Gottesdiener","year":"2000","unstructured":"Gottesdiener K, Schnitzer T, Fisher C, et al: Treatment with MK-663, a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee that was sustained over three months. Ann Rheum Dis. 2000, 59: 133 [Abstract]-","journal-title":"Ann Rheum Dis"},{"key":"18_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000046212","volume":"21","author":"DC Brater","year":"2001","unstructured":"Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001, 21: 1-15. 10.1159\/000046212.","journal-title":"Am J Nephrol"},{"key":"18_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.pa.33.040193.002251","volume":"32","author":"MD Murray","year":"1993","unstructured":"Murray MD, Brater DC: Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993, 32: 435-465.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"18_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999, 282: 1929-1933. 10.1001\/jama.282.20.1929.","journal-title":"JAMA"},{"key":"18_CR17","doi-asserted-by":"publisher","first-page":"28S","DOI":"10.1016\/S0002-9343(00)00683-5","volume":"110","author":"F Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001, 110: 28S-32S. 10.1016\/S0002-9343(00)00683-5.","journal-title":"Am J Med"},{"key":"18_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective cox-2 inhibitors. JAMA. 2001, 286: 954-959. 10.1001\/jama.286.8.954.","journal-title":"JAMA"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"S226 [Abstract]","DOI":"10.1002\/1529-0131(200001)43:1<226::AID-ANR27>3.0.CO;2-Q","volume":"43","author":"SP Curtis","year":"2000","unstructured":"Curtis SP, Maldonado-Cocco J, Lozada B, et al: Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis. Arthritis Rheum. 2000, 43: S226 [Abstract]-","journal-title":"Arthritis Rheum"}],"container-title":["BMC Family Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-3-10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2296-3-10\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-3-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-3-10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:46:53Z","timestamp":1726242413000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/1471-2296-3-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,22]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2002,12]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1186\/1471-2296-3-10","relation":{},"ISSN":["1471-2296"],"issn-type":[{"value":"1471-2296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,22]]},"assertion":[{"value":"23 January 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"10"}}